Vivace Therapeutics, Inc. logo
SEC Form D filing

Vivace Therapeutics, Inc.

Biotech · Series B · Regulation D 506(b) · CA · Filed March 12, 2025

Websitevivacetherapeutics.com
Offering amount
$35.0M
Exemption
Reg D 506(b)
Issuer state
CA
Filing date
March 12, 2025
Signature date
—
CIK
0001630575

Summary

Vivace Therapeutics drug development; $35M indicates series-b biotech venture.

Source

View on SEC EDGAR →Get alerts for filings like this →

FormDFlow indexes public-disclosure data from SEC EDGAR. Nothing on this page is investment advice.